{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T23:19:14Z","timestamp":1793488754657,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,5,30]],"date-time":"2018-05-30T00:00:00Z","timestamp":1527638400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s00393-018-0476-8","type":"journal-article","created":{"date-parts":[[2018,5,25]],"date-time":"2018-05-25T06:39:03Z","timestamp":1527230343000},"page":"429-441","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["S3-Leitlinie zur Behandlung der Polymyalgia rheumatica","S3 guidelines on treatment of polymyalgia rheumatica"],"prefix":"10.1007","volume":"77","author":[{"name":"DGRh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Buttgereit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"DGG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"DGOOC","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Rheuma-Liga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"DGIM","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"SGR","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"DGPMR","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"\u00d6GR","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Brabant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Dinges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Hiemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kaplani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Kiltz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Kyburz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rei\u00dfhauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Weseloh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Dejaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,30]]},"reference":[{"issue":"7","key":"476_CR1","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00393-016-0105-3","volume":"75","author":"C Dejaco","year":"2016","unstructured":"Dejaco C, Matteson EL, Buttgereit F (2016) Diagnostics and treatment of polymyalgia rheumatica. Z\u00a0Rheumatol 75(7):687\u2013700","journal-title":"Z Rheumatol"},{"issue":"10","key":"476_CR2","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1080\/1744666X.2016.1178572","volume":"12","author":"F Muratore","year":"2016","unstructured":"Muratore F, Pazzola G, Pipitone N, Salvarani C (2016) Recent advances in the diagnosis and treatment of polymyalgia rheumatica. Expert Rev Clin Immunol 12(10):1037\u20131045","journal-title":"Expert Rev Clin Immunol"},{"issue":"22","key":"476_CR3","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1001\/jama.2016.5444","volume":"315","author":"F Buttgereit","year":"2016","unstructured":"Buttgereit F, Dejaco C, Matteson EL, Dasgupta B (2016) Polymyalgia rheumatica and giant cell arteritis: a systematic review. JAMA 315(22):2442\u20132458","journal-title":"JAMA"},{"issue":"9","key":"476_CR4","doi-asserted-by":"publisher","first-page":"ITC65","DOI":"10.7326\/AITC201705020","volume":"166","author":"EL Matteson","year":"2017","unstructured":"Matteson EL, Dejaco C (2017) Polymyalgia rheumatica. Ann Intern Med 166(9):ITC65\u2013ITC80","journal-title":"Ann Intern Med"},{"issue":"10","key":"476_CR5","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1136\/annrheumdis-2015-207492","volume":"74","author":"C Dejaco","year":"2015","unstructured":"Dejaco C, Singh YP, Perel P, Hutchings A, Camellino D, Mackie S et\u00a0al (2015) 2015 recommendations for the management of polymyalgia rheumatica: a\u00a0European League Against Rheumatism\/American College of Rheumatology collaborative initiative. Ann Rheum Dis 74(10):1799\u20131807","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"476_CR6","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.39333","volume":"67","author":"C Dejaco","year":"2015","unstructured":"Dejaco C, Singh YP, Perel P, Hutchings A, Camellino D, Mackie S et\u00a0al (2015) 2015 recommendations for the management of polymyalgia rheumatica: a\u00a0European League Against Rheumatism\/American College of Rheumatology collaborative initiative. Arthritis Rheumatol 67(10):2569\u20132580","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"476_CR7","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D et al (2011) GRADE guidelines 6. Rating the quality of evidence\u2014imprecision. J\u00a0Clin Epidemiol 64(12):1283\u20131293","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"476_CR8","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J et\u00a0al (2011) GRADE guidelines: 3. Rating the quality of evidence. J\u00a0Clin Epidemiol 64(4):401\u2013406","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"476_CR9","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1136\/annrheumdis-2015-207578","volume":"74","author":"C Dejaco","year":"2015","unstructured":"Dejaco C, Singh YP, Perel P, Hutchings A, Camellino D, Mackie S et\u00a0al (2015) Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a\u00a0systematic literature review informing the 2015 European League Against Rheumatism\/American College of Rheumatology recommendations for the management of polymyalgia rheumatica. Ann Rheum Dis 74(10):1808\u20131817","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"476_CR10","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1002\/art.39740","volume":"68","author":"L Lally","year":"2016","unstructured":"Lally L, Forbess L, Hatzis C, Brief Report SR (2016) A prospective open-label phase IIa trial of tocilizumab in the treatment of polymyalgia rheumatica. Arthritis Rheumatol 68(10):2550\u20132554","journal-title":"Arthritis Rheumatol"},{"issue":"13","key":"476_CR11","doi-asserted-by":"publisher","first-page":"E495","DOI":"10.1503\/cmaj.140266","volume":"186","author":"AT Hancock","year":"2014","unstructured":"Hancock AT, Mallen CD, Muller S, Belcher J, Roddy E, Helliwell T et\u00a0al (2014) Risk of vascular events in patients with polymyalgia rheumatica. CMAJ 186(13):E495\u2013E501","journal-title":"CMAJ"},{"issue":"1","key":"476_CR12","doi-asserted-by":"publisher","first-page":"28","DOI":"10.5606\/ArchRheumatol.2015.4643","volume":"30","author":"FG Yurdakul","year":"2015","unstructured":"Yurdakul FG, Bodur H, Sivas F, Baskan B, Eser F, Yilmaz O (2015) Clinical features, treatment and monitoring in patients with polymyalgia rheumatica. Arch Rheumatol 30(1):28\u201333","journal-title":"Arch. Rheumatol."},{"issue":"5","key":"476_CR13","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s11739-017-1626-8","volume":"12","author":"M Bellan","year":"2017","unstructured":"Bellan M, Boggio E, Sola D, Gibbin A, Gualerzi A, Favretto S et\u00a0al (2017) Association between rheumatic diseases and cancer: results from a\u00a0clinical practice cohort study. Intern Emerg Med 12(5):621\u2013627","journal-title":"Intern Emerg Med"},{"issue":"10","key":"476_CR14","first-page":"2143","volume":"29","author":"G Myklebust","year":"2002","unstructured":"Myklebust G, Wilsgaard T, Jacobsen BK, Gran JT (2002) No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls. J\u00a0Rheumatol 29(10):2143\u20132147","journal-title":"J Rheumatol"},{"issue":"8","key":"476_CR15","first-page":"1335","volume":"20","author":"HJ Haga","year":"1993","unstructured":"Haga HJ, Eide GE, Brun J, Johansen A, Langmark F (1993) Cancer in association with polymyalgia rheumatica and temporal arteritis. J\u00a0Rheumatol 20(8):1335\u20131339","journal-title":"J Rheumatol"},{"issue":"3","key":"476_CR16","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/art.10402","volume":"47","author":"G Haugeberg","year":"2002","unstructured":"Haugeberg G, Dovland H, Johnsen V (2002) Increased frequency of malignancy found in patients presenting with new-onset polymyalgic symptoms suggested to have polymyalgia rheumatica. Arthritis Rheum 47(3):346\u2013347","journal-title":"Arthritis Rheum"},{"issue":"6","key":"476_CR17","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/00124743-199612000-00002","volume":"2","author":"JE Naschitz","year":"1996","unstructured":"Naschitz JE, Slobodin G, Yeshurun D, Rozenbaum M, Rosner I (1996) A polymyalgia rheumatica-like syndrome as presentation of metastatic cancer. J\u00a0Clin Rheumatol 2(6):305\u2013308","journal-title":"J Clin Rheumatol"},{"issue":"20","key":"476_CR18","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1001\/archinte.1997.00440410115014","volume":"157","author":"JE Naschitz","year":"1997","unstructured":"Naschitz JE, Slobodin G, Yeshurun D, Rozenbaum M, Rosner I (1997) Atypical polymyalgia rheumatica as a\u00a0presentation of metastatic cancer. Arch Intern Med 157(20):2381","journal-title":"Arch Intern Med"},{"issue":"2","key":"476_CR19","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/rheumatology\/37.2.189","volume":"37","author":"B Dasgupta","year":"1998","unstructured":"Dasgupta B, Dolan AL, Panayi GS, Fernandes L (1998) An initially double-blind controlled 96 week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica. Br J Rheumatol 37(2):189\u2013195","journal-title":"Br J Rheumatol"},{"issue":"1","key":"476_CR20","doi-asserted-by":"publisher","first-page":"e000426","DOI":"10.1136\/rmdopen-2016-000426","volume":"3","author":"M Cutolo","year":"2017","unstructured":"Cutolo M, Hopp M, Liebscher S, Dasgupta B, Buttgereit F (2017) Modified-release prednisone for polymyalgia rheumatica: a\u00a0multicentre, randomised, active-controlled, double-blind, parallel-group study. Rmd Open 3(1):e426","journal-title":"Rmd Open"},{"issue":"3","key":"476_CR21","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1136\/annrheumdis-2016-210002","volume":"76","author":"EM Miloslavsky","year":"2017","unstructured":"Miloslavsky EM, Naden RP, Bijlsma JW, Brogan PA, Brown ES, Brunetta P et\u00a0al (2017) Development of a\u00a0Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. Ann Rheum Dis 76(3):543\u2013546","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"476_CR22","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1136\/ard.2009.124958","volume":"69","author":"MC Goes van der","year":"2010","unstructured":"van der Goes MC, Jacobs JW, Boers M, Andrews T, Blom-Bakkers MA, Buttgereit F et al (2010) Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis 69(11):1913\u20131919","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"476_CR23","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1002\/art.1780401115","volume":"40","author":"AL Dolan","year":"1997","unstructured":"Dolan AL, Moniz C, Dasgupta B, Li F, Mackintosh C, Todd P et\u00a0al (1997) Effects of inflammation and treatment on bone turnover and bone mass in polymyalgia rheumatica. Arthritis Rheum 40(11):2022\u20132029","journal-title":"Arthritis Rheum"},{"issue":"5","key":"476_CR24","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1136\/ard.53.5.331","volume":"53","author":"MA Cimmino","year":"1994","unstructured":"Cimmino MA, Moggiana G, Montecucco C, Caporali R, Accardo S (1994) Long term treatment of polymyalgia rheumatica with deflazacort. Ann Rheum Dis 53(5):331\u2013333","journal-title":"Ann Rheum Dis"},{"key":"476_CR25","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1196\/annals.1351.030","volume":"1069","author":"MA Cimmino","year":"2006","unstructured":"Cimmino MA, Parodi M, Caporali R, Montecucco C (2006) Is the course of steroid-treated polymyalgia rheumatica more severe in women? Ann N Y Acad Sci 1069:315\u2013321","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"476_CR26","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/0002-9343(85)90309-2","volume":"79","author":"WT Ayoub","year":"1985","unstructured":"Ayoub WT, Franklin CM, Torretti D (1985) Polymyalgia rheumatica. Duration of therapy and long-term outcome. Am J Med 79(3):309\u2013315","journal-title":"Am J Med"},{"issue":"5","key":"476_CR27","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/fampra\/cmn044","volume":"25","author":"K Barraclough","year":"2008","unstructured":"Barraclough K, Liddell WG, du Toit J, Foy C, Dasgupta B, Thomas M et\u00a0al (2008) Polymyalgia rheumatica in primary care: a\u00a0cohort study of the diagnostic criteria and outcome. Fam Pract 25(5):328\u2013333","journal-title":"Fam Pract"},{"issue":"1","key":"476_CR28","first-page":"65","volume":"32","author":"HM Kremers","year":"2005","unstructured":"Kremers HM, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE (2005) Relapse in a\u00a0population based cohort of patients with polymyalgia rheumatica. J\u00a0Rheumatol 32(1):65\u201373","journal-title":"J Rheumatol"},{"issue":"5","key":"476_CR29","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1136\/ard.58.5.303","volume":"58","author":"C Salvarani","year":"1999","unstructured":"Salvarani C, Boiardi L, Mantovani V, Ranzi A, Cantini F, Olivieri I et al (1999) HLA-DRB1 alleles associated with polymyalgia rheumatica in northern Italy: correlation with disease severity. Ann Rheum Dis 58(5):303\u2013308","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"476_CR30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1053\/sarh.2000.8366","volume":"30","author":"F Cantini","year":"2000","unstructured":"Cantini F, Salvarani C, Olivieri I, Macchioni L, Ranzi A, Niccoli L et al (2000) Erythrocyte sedimentation rate and C\u2011reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a\u00a0prospective follow-up study. Semin Arthritis Rheum 30(1):17\u201324","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"476_CR31","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1007\/s00296-012-2580-4","volume":"33","author":"JH Lee","year":"2013","unstructured":"Lee JH, Choi ST, Kim JS, Yoon BY, Kwok SK, Kim HS et\u00a0al (2013) Clinical characteristics and prognostic factors for relapse in patients with polymyalgia rheumatica (PMR). Rheumatol Int 33(6):1475\u20131480","journal-title":"Rheumatol Int"},{"issue":"5","key":"476_CR32","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1080\/030097401753180327","volume":"30","author":"G Myklebust","year":"2001","unstructured":"Myklebust G, Gran JT (2001) Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis. A prospective two-year study in 273 patients. Scand J Rheumatol 30(5):260\u2013267","journal-title":"Scand J Rheumatol"},{"issue":"3","key":"476_CR33","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1001\/archinte.1997.00440240081012","volume":"157","author":"MA Gonzalez-Gay","year":"1997","unstructured":"Gonzalez-Gay MA, Rodriguez-Valverde V, Blanco R, Fernandez-Sueiro JL, Armona J, Figueroa M et al (1997) Polymyalgia rheumatica without significantly increased erythrocyte sedimentation rate. A more benign syndrome. Arch Intern Med 157(3):317\u2013320","journal-title":"Arch Intern Med"},{"issue":"7","key":"476_CR34","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1002\/1529-0131(199807)41:7<1221::AID-ART12>3.0.CO;2-W","volume":"41","author":"C Salvarani","year":"1998","unstructured":"Salvarani C, Cantini F, Macchioni P, Olivieri I, Niccoli L, Padula A et\u00a0al (1998) Distal musculoskeletal manifestations in polymyalgia rheumatica: a\u00a0prospective followup study. Arthritis Rheum 41(7):1221\u20131226","journal-title":"Arthritis Rheum"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-018-0476-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-018-0476-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-018-0476-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T19:29:11Z","timestamp":1559158151000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-018-0476-8"}},"subtitle":["Evidenzbasierte Leitlinie der Deutschen Gesellschaft f\u00fcr Rheumatologie (DGRh), der \u00d6sterreichischen Gesellschaft f\u00fcr Rheumatologie und Rehabilitation (\u00d6GR) und der Schweizerischen Gesellschaft f\u00fcr Rheumatologie (SGR) und der beteiligten medizinisch-wissenschaftlichen Fachgesellschaften und weiterer Organisationen","Evidence-based guidelines of the German Society of Rheumatology (DGRh), the Austrian Society of Rheumatology and Rehabilitation (\u00d6GR) and the Swiss Society of Rheumatology (SGT) and participating medical scientific specialist societies and other organizations"],"short-title":[],"issued":{"date-parts":[[2018,5,30]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["476"],"URL":"https:\/\/doi.org\/10.1007\/s00393-018-0476-8","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,30]]},"assertion":[{"value":"30 May 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F.\u00a0Buttgereit: Berater- und\/oder Referentenhonorare durch die Firmen Horizon Pharma, Mundipharma Int Ltd. und Sanofi; Co-principal investigator\/site investigator bei einer von Mundipharma durchgef\u00fchrten, internationalen PMR-Studie zur Untersuchung der Wirkungen von MR-Prednison. T.\u00a0Brabant: Berater- und\/oder Referentenhonorare durch die Firmen Lilly, Novartis und Amgen. U.\u00a0Kiltz: Berater- und\/oder Referentenhonorare durch die Firmen AbbVie, Chugai, Gr\u00fcnenthal, Janssen, MSD, Novartis, Pfizer, Roche und UCB. Forschungsunterst\u00fctzungen (unrestricted grant) durch AbbVie und Pfizer. D.\u00a0Kyburz: Berater und\/oder Referentenhonorare durch die Firmen AbbVie, BMS, Celgene, Lilly, Menarini, MSD, Novartis, Pfizer, Roche, UCB. M.\u00a0Schneider: Honorare f\u00fcr Beratung, Vortr\u00e4ge und Drittmittel: AbbVie, AstraZeneca, BMS, Boehringer-Ingelheim, Chugai, GSK, Janssen-Cilag, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi-Aventis, UCB. C.\u00a0Dejaco: Berater- und\/oder Referentenhonorare durch die Firmen MSD, Pfizer, UCB, AbbVie, Roche, Novartis, Lilly, Celgene, Merck, Signatis Pharma und GSK. Forschungsunterst\u00fctzung (unrestricted grant) durch Pfizer und MSD. H.\u00a0Dinges, I.\u00a0Hiemer, M.\u00a0Kaplani, A.\u00a0Rei\u00dfhauer und C.\u00a0Weseloh geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}